Pfizer Collaboration - Triple Negative Breast Cancer (TNBC)
In 2018, Zenith entered into a clinical trial collaboration with Pfizer in developing the combination of ZEN-3694 + Pfizer’s poly-ADP ribose polymerase inhibitor (PARPi) – talazoparib – for TNBC. A Phase 2 trial is ongoing, with Zenith and Pfizer sharing the costs equally. Zenith retains all rights to ZEN-3694. Ongoing data were recently presented at the San Antonio Breast Cancer Symposium and future data will be presented at upcoming major scientific conferences. Additional information on this clinical trial can be accessed HERE.
Newsoara BioPharm Co., Ltd. (Newsoara) - China Regional Partnership
In 2019, Zenith entered into a licensing agreement with Newsoara to develop ZEN-3694 for the China, Hong Kong, Taiwan and Macau markets. Newsoara owns 100% of the development and commercialization rights for ZEN-3694 in these markets and is responsible for all associated costs. In exchange for these rights, Zenith received an upfront payment and is eligible for development and commercial milestone payments and royalties. Zenith and Newsoara are currently collaborating to develop ZEN-3694 + enzalutamide in combination to treat metastatic castration resistant prostate cancer (mCRPC) in a planned China/USA Phase 2b randomized trial. More information can be found HERE.
National Cancer Institute (NCI) Clinical Research and Development Collaboration
In 2020, Zenith and NCI executed a cooperative and research collaboration agreement to develop ZEN-3694 for multiple oncology indications with different targeted combination agents. The collaboration will benefit from NCI’s extensive clinical development and regulatory infrastructure and the majority of the costs associated with the collaboration trials will be funded by NCI. The first clinical trial will test the combination of ZEN-3694 and Bristol Myers Squibb’s immune checkpoint inhibitors, nivolumab and ipilmumab, in resistant ovarian cancer. Additional trials are in the planning stages. More information can be found HERE.
University of California San Francisco / Merck Collaboration – mCRPC
UCSF is collaborating with Zenith and Merck to test the combination of ZEN-3694 + Merck’s immune checkpoint inhibitor, pembrolizumab, in metastatic castration-resistant prostate cancer patients who are androgen receptor signaling independent. In this Phase 2 clinical trial, patients will be dosed with a triple combination of ZEN-3694, Merck’s pembrolizumab and Pfizer’s enzalutamide. Additional information on this clinical trial can be accessed HERE.
Contact
Sanjay Lakhotia, Ph.D., MBA
Chief Business Officer
E: info@zenithepigenetics.com
T: 1 (587) 390-7865
